Select Location
What is your delivery location?
We need your delivery location to continue browsing
Select Location
We need your delivery location to continue browsing
Prescription Required
Natco Pharma
30 Tablets
Exemestane
Keep in cold place
Delivering To:
Overview
Xtane 25 mg is a hormone therapy-based anticancer medication that contains the active ingredient Exemestane. This medication is used to treat hormone-dependent early breast cancer in postmenopausal women after they have completed 2-3 years of treatment with Tamoxifen. It is also effective for treating hormone-dependent advanced breast cancer. It belongs to the class of drugs known as aromatase inhibitors, which lower estrogen levels and consequently inhibit the proliferation of cancer cells. It is a prescription-based medication whose dosage is decided by the doctor.
Breast Cancer
Breast cancer
Xtane 25mg Tablet may cause some side effects that vary from one patient to another. Most side effects do not require any medical attention and disappear as your body adjusts to the medicine.
Common side effects include:
Swelling of arms and feet
Shortness of breath
Decrease in WBCs
Extreme fatigue
Low mental health
High cholesterol level
Dizziness
Headache
Wheezing
Hair loss
Joint and muscle pain
Trouble sleeping
Seek medical attention in case of any unusual or severe side effects immediately.
The dosage of Xtane 25 mg is prescribed by a doctor based on the cancer stage and the patient’s overall health. This medicine should be taken orally after a meal. Swallow it as a whole. Do not chew, crush, or break it. In case of an overdose, contact your doctor immediately.
Xtane 25 mg belongs to the class of drugs known as aromatase inhibitors. Aromatase is an enzyme that helps in the conversion of androgens to estrogen in post-menopausal women. Estrogen encourages cancer cells to grow uncontrollably. Xtane works by binding to the aromatase enzyme, inhibiting its ability to produce estrogen. This results in a reduction of estrogen levels. Additionally, Xtane not only decreases tumor size but also blocks cell proliferation.
Alcohol
unsafe
Avoid the consumption of alcohol while taking Xtane 25mg Tablet, as alcohol can reduce the effectiveness of the medicine and worsen the symptoms
Pregnancy
consult your doctor
Do not take the Xtane 25mg Tablet without consulting the doctor in case of pregnancy, as it is an unsafe medicine during this period.
Breast Feeding
consult your doctor
Xtane 25mg Tablet is unsafe to use during breastfeeding as it may cause toxicity to the baby.
Driving
danger
Xtane 25mg Tablet may cause side effects such as dizziness or impaired concentration, which could affect your ability to drive safely. So it's better to avoid driving or operating heavy machinery.
Kidney
caution
Consumption of Xtane 25mg Tablet should be avoided without informing the doctor if you have any kidney-related issues.
Liver
caution
Consumption of Xtane 25mg Tablet should be avoided without informing the doctor if you have any liver-related issues.
If you forget to take a dose of Xtane 25mg Tablet, consult your doctor. Don’t double up the next dose to cope with the missed one unless your doctor recommends it.
Xtane 25mg tablet is an anticancer capsule that is primarily used in the treatment of breast cancer in postmenopausal women.
Xtane 25mg tablets are taken orally once every day after a meal.
It is advisable to store the Xtane tablets at a place below 30°C.
Avoid drinking alcohol during the treatment with Xtane 25mg even though no interactions of both are known.
The doctor decides for how long the treatment with Xtane 25mg will continue depending on the stage, and health of the patient.
It is not known whether it is safe or not. Please consult your doctor before consuming alcohol while taking Xtane 25mg Tablet.
Memory impairments have been reported in a few patients. Consult your doctor if you face problems with concentration, loss of memory, or are confused.
No, children below 18 years of age are not advised to take Xtane 25mg Tablet as it results in severe complications.
Xtane 25mg Tablet is not recommended for breastfeeding unless it is necessary.
At our pharmacy, your health is our top priority. All of our medicines are safe, effective, and approved by leading health authorities. We partner exclusively with reliable and reputable manufacturers, ensuring the highest quality standards in every product we deliver.
Enjoy the convenience of fast home delivery, secure packaging, and affordable prices—plus special discounts on bulk orders. We’re proud to offer international shipping to a wide range of countries across Asia, Europe, Africa, the Americas, and beyond, making trusted healthcare accessible no matter where you are.
Whether you're a patient or a healthcare provider, you can order with confidence and compassion. Our goal is to ensure that quality healthcare reaches everyone, everywhere.
We currently ship to:
Barbados, Haiti, Trinidad and Tobago, Mexico, Bahamas, Ecuador, Peru, Chile, Brazil, Colombia, Philippines, U.K., USA, Kuwait, Saudi Arabia, UAE, Oman, Qatar, Japan, Ireland, Russia, China, France, Australia, Lithuania, Nigeria, Romania, Algeria, Canada, Singapore, Thailand, Hong Kong, Bahrain, Jordan, Indonesia, Hungary, Moldova, Bulgaria, Azerbaijan, Congo, Ethiopia, Lebanon, Morocco, Mozambique, South Korea, Sri Lanka, Belarus, Mongolia, Malaysia, Vietnam, Tunisia, Zambia, and Israel.
Experience the quality everyone’s talking about – order today!
1. Goss, P. E., Ingle, J. N., Alés-Martínez, J. E., Cheung, A. M., Chlebowski, R. T., Wactawski-Wende, J., ... & Richardson, H. (2011). Exemestane for breast-cancer prevention in postmenopausal women. New England Journal of Medicine, 364(25), 2381-2391.
2. Scott, L. J., & Wiseman, L. R. (1999). Exemestane. Drugs, 58(4), 675-680.
3. Deeks, E. D., & Scott, L. J. (2009). Exemestane: a review of its use in postmenopausal women with breast cancer. Drugs, 69(7), 889-918.
4. Di Salle, E., Ornati, G., Giudici, D., Lassus, M., Evans, T. R. J., & Coombes, R. C. (1992). Exemestane (FCE 24304), a new steroidal aromatase inhibitor. The Journal of Steroid Biochemistry and Molecular Biology, 43(1-3), 137-143.
5. Lønning, P. E. (2001). Exemestane: a review of its clinical efficacy and safety. The breast, 10(3), 198-208.
6. Buzdar, A. (2000). Exemestane in advanced breast cancer. Anti-cancer drugs, 11(8), 609-616.
7. Fallowfield, L. J., Bliss, J. M., Porter, L. S., Price, M. H., Snowdon, C. F., Jones, S. E., ... & Hall, E. (2006). Quality of life in the intergroup exemestane study: a randomized trial of exemestane versus continued tamoxifen after 2 to 3 years of tamoxifen in postmenopausal women with primary breast cancer. Journal of Clinical Oncology, 24(6), 910-917.
Natco Pharma
Written By
Venika Choudhary
Medical Content Writer @ Magicine Pharma
I hold an M.Sc. in Microbiology and have a strong academic foundation in microbial sciences and applied biotechnology. I began my career with extensive hands-on research at CSIR laboratories, focusing on fungal enzyme production, studying fungal diversity in various ecosystems, and developing bio-pesticides as sustainable alternatives to chemical pesticides. This work deepened my understanding of fungal biology, bioactive compounds, and their pharmaceutical and agricultural applications. Transitioning from research, I now work as a medical content writer, where I combine my scientific expertise with a passion for clear and reliable healthcare communication. I apply my research background to create patient-friendly, compliant content for pharmaceutical companies and healthcare platforms, ensuring science is both trustworthy and accessible. Specializing in clear, accurate, and engaging content, I help patients make informed decisions and support pharmaceutical companies in delivering trusted information. Whether writing product descriptions, crafting disease awareness articles, or composing drug information leaflets, I consistently meet regulatory standards and address audience needs, making my content an asset for healthcare brands.
Reviewed By
Dr. Aditya Sarin - MBBS, MD, DrNB - Consultant Medical Oncology
Dr. Aditya Sarin, MBBS, MD, DrNB, is a highly qualified medical oncologist with profound research and clinical expertise, currently working at Sir Ganga Ram Hospital, New Delhi. He is also a member of the European Society of Medical Oncology (ESMO), a non-profit European organization dedicated to eradicating cancer by promoting comprehensive cancer care and advancing medical oncology. He has been honored with several awards, including the International Cancer Foundation scholarship (ESMO congress, 2022) and Young Medical Oncologist of the Year (Times of India, 2024). He is well-known for his breakthrough in oncology. Dr. Sarin is passionate about converting complex health information into a concise and clear form that is understandable to everyone, aiming to create awareness and cancer care among people.